Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341506 | 0.79 | HDAC1 (0.36) | HCAR3HDAC1HDAC6ALDH1A1MAPK1 | |
| SCHEMBL22402939 | 0.76 | MAPK1 (0.42) | HDAC1HDAC6ALDH1A1MAPK1LMNA | |
| SCHEMBL16249204 | 0.71 | TDP1 (0.47) | ALDH1A1KDM4EMAPK1LMNAPOLB | |
| SCHEMBL3671626 | 0.71 | — | — | |
| SCHEMBL8923370 | 0.71 | HCAR3 (0.31) | HCAR3 | |
| SCHEMBL29027809 | 0.70 | ALDH1A1 (0.34) | HCAR3ALDH1A1KDM4EGRNSORT1 | |
| SCHEMBL20128067 | 0.69 | MAPK1 (0.33) | ALDH1A1MAPK1FAAH | |
| Ammonia Solution, Strong SCHEMBL4751250 | 0.69 | LMNA (0.30) | LMNA | |
| SCHEMBL507145 | 0.67 | — | — | |
| SCHEMBL31402456 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240586-A1 | Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-5597929-A | Production process of 2-(tetrazol-5-yl)-4-oxo-4H-benzopyran | SUMITOMO CHEMICAL CO., LTD. (JP) | 1997-01-28 | — | — | US | disclosed |
| EP-0716088-A1 | PROCESS FOR PRODUCING 2-(TETRAZOL-5-YL)-4-OXO-4H-BENZOPYRANS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240586-A1 | Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof | GPBAR1, NR1H4, SLC10A1 | HCAR3 58/4885HDAC1 1771/4885HDAC6 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.